TFS International announces that Dr Suzanne Pavon is now Executive Vice President, Quality Assurance. Dr Pavon is an entrepreneurial, quality focused, senior executive with over 20 years’ global experience in the CRO, biotechnology and pharmaceutical industries.
Her most recent role was with Piramal Critical Care (PCC), the third largest producer of inhaled anesthetics and a global player in hospital generics. She held the executive position of Global Quality Director, across PCC manufacturing sites and global offices, and was responsible for the quality management and compliance in more than 113 countries and 83 business partners.
“We are delighted to welcome Suzanne into our TFS family where she will lead our quality assurance and compliance activities,” said Dr János Filakovský, Chief Executive Officer. “Suzanne has over 20 years’ experience in global, cross-functional, cross-geographic Biopharmaceutical Product Development. She brings with her a dynamism and leadership style that will have a significantly positive impact at TFS.”
The majority of Dr Pavon's experience has been in international roles and she has lived and worked in the US, Canada, Jordan, UK, Belgium, France and the Netherlands. She has managed diverse cultural teams and is proud of her record of achievement in quality improvement, team development, simplification of processes and business growth. Dr Pavon has proven leadership skills with an ability to manage quality and compliance through significant change, whilst achieving key quality and business performance targets.
Commenting on her new role: “I am extremely thrilled to be joining TFS International, one of the leading, mid-sized global CROs. I will be responsible to safeguard the company’s compliance and risk and will be committed to ensuring the highest quality in our services and projects whilst having patients and customers in mind.
I am passionate about combining business strategy and quality mindset, talent development, simplification, operational and quality excellence to be a leading differentiator in our business."
Dr Pavon will be based at the TFS offices in London. The company operates operates on a global scale, in 21 countries throughout Europe and North America, employing more than 700 professionals. It is a leading mid-size clinical CRO, providing global clinical development solutions to key therapeutic areas including oncology, dermatology, ophthalmology, immunology, cardiology, CNS and endocrinology.
